Microgravity Life Sciences:
Investment Event

Could medicines manufactured in space transform how treatments are delivered on Earth?

Manufacturing medicines in space can sound like a distant prospect. In reality, it is becoming a serious area of commercial life sciences innovation, with the potential to improve how some medicines are formulated, administered and experienced by patients.

The market for space-based research, testing and manufacturing in life sciences and pharma is already worth more than £600 million a year, based on the real costs of taking projects to the International Space Station, currently the only comparable market. The commercial biopharmaceutical products this activity enables are forecast to be worth more than £26 billion a year by 2034. Set against a UK life sciences and biopharma sector that already generates over £200 billion in turnover annually, this represents a substantial emerging opportunity. With no established European market leader, there is a clear opportunity for the UK to help shape this sector from an early stage.

Sources: current market value based on launch and payload handling costs for International Space Station projects, the only directly comparable market at present; £26 billion forecast from Growth Market Reports, Space-Based Biopharmaceuticals Market Outlook (2024); UK life sciences and biopharma turnover from the Office for Life Sciences (2023/24).

But why manufacture medicines in space at all?

The potential of microgravity

On Earth, gravity affects how biological materials behave and how pharmaceutical crystals form. In the microgravity environment of Low Earth Orbit, researchers can produce crystals with different structures and properties.

This could enable certain medicines to be formulated using smaller and more uniform particles. In some cases, this may allow a treatment that currently requires an intravenous infusion in a clinical setting to be delivered through a simpler injection.

The potential impact extends beyond the medicine itself.

Treatments that can be administered more easily could reduce the time patients spend travelling to and receiving care in hospital. They could also create opportunities for more treatment to be delivered in community or home settings, while reducing pressure on specialist clinical facilities.

For healthcare systems, the commercial value will depend not only on whether a medicine works, but also on whether it can improve patient outcomes, reduce the overall cost of delivering care and support a better treatment experience.

A new commercial pathway

The scientific opportunity is significant, but manufacturing medicines in space creates an unfamiliar and complex route to market.

Pharmaceutical products must meet demanding regulatory and quality requirements. When manufacturing takes place in orbit, the conventional journey from laboratory to patient expands to include launch preparation, payload handling, spaceflight, production in microgravity, reentry and return to the laboratory.

At every stage, the integrity of the product must be protected and evidenced.

This creates a need for coordinated expertise across life sciences, pharmaceutical regulation, space engineering, logistics and manufacturing. It also creates commercial opportunities throughout a new and developing supply chain.

PlastronCRO has developed BioConOps, a biological concept of operations framework designed to connect the requirements of life sciences manufacturing with the operational demands of a space mission.

The framework considers issues including regulatory compliance, payload handling, monitoring and chain of custody throughout the complete journey from laboratory to space and back again.

This work is helping to establish the practical infrastructure needed to move space manufactured medicines from scientific possibility towards a scalable commercial proposition.

Why the UK and why now?

The UK combines internationally recognised life sciences expertise with a growing space sector, established regulatory capability and a strong investment community.

However, leadership in this market is not yet settled. Early coordination between investors, scientists, regulators and space technology businesses will be essential if the UK is to secure a meaningful position.

PlastronCRO, Babraham Research Campus and Space East are bringing together investors and industry leaders to examine the opportunity, the work already underway and what will be required to build a commercially viable UK sector.

Investment and Insights Event for Space Manufactured Medicines

Investors and strategic partners are invited to an exclusive morning event exploring:

• The commercial opportunity presented by space manufactured medicines
• The potential patient and healthcare benefits
• The infrastructure, regulatory pathways and partnerships required
• The UK’s opportunity to become a global leader in this emerging market
• Where investment could help accelerate the development of the sector

Attendance is limited to 30 guests.